<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
		>
<channel>
	<title>Comments on: Dreaming of inactivated poliovirus vaccine</title>
	<atom:link href="http://www.virology.ws/2009/02/26/dreaming-inactivated-poliovirus-vaccine/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.virology.ws/2009/02/26/dreaming-inactivated-poliovirus-vaccine/</link>
	<description>About viruses and viral disease</description>
	<lastBuildDate>Sat, 11 Feb 2012 17:38:00 +0000</lastBuildDate>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.1</generator>
	<item>
		<title>By: WHO Finally Gets The Memo, but Leslie&#39;s Still Missing It &#124; Alan Dove, Ph.D.</title>
		<link>http://www.virology.ws/2009/02/26/dreaming-inactivated-poliovirus-vaccine/comment-page-1/#comment-23573</link>
		<dc:creator>WHO Finally Gets The Memo, but Leslie&#39;s Still Missing It &#124; Alan Dove, Ph.D.</dc:creator>
		<pubDate>Tue, 26 Oct 2010 18:39:40 +0000</pubDate>
		<guid isPermaLink="false">http://www.virology.ws/?p=736#comment-23573</guid>
		<description>[...] a different vaccine. To understand the sarcasm in the previous sentence, take five minutes to read Vince&#8217;s post, then come back [...]</description>
		<content:encoded><![CDATA[<p>[...] a different vaccine. To understand the sarcasm in the previous sentence, take five minutes to read Vince&#8217;s post, then come back [...]</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: freeannualcreditreport</title>
		<link>http://www.virology.ws/2009/02/26/dreaming-inactivated-poliovirus-vaccine/comment-page-1/#comment-19526</link>
		<dc:creator>freeannualcreditreport</dc:creator>
		<pubDate>Sun, 03 Jan 2010 03:13:52 +0000</pubDate>
		<guid isPermaLink="false">http://www.virology.ws/?p=736#comment-19526</guid>
		<description>Quite interesting for this conversation.&lt;br&gt;&lt;a href=&quot;http://www.jmorganmarketing.com/the-twitter-attack-on-jeremiah-owyang-community-defense/&quot; rel=&quot;nofollow&quot;&gt;free credit report&lt;/a&gt;, &lt;a href=&quot;http://investorial.com/headline/canada-loses-more-credit/&quot; rel=&quot;nofollow&quot;&gt;free credit report&lt;/a&gt;</description>
		<content:encoded><![CDATA[<p>Quite interesting for this conversation.<br /><a href="http://www.jmorganmarketing.com/the-twitter-attack-on-jeremiah-owyang-community-defense/" rel="nofollow">free credit report</a>, <a href="http://investorial.com/headline/canada-loses-more-credit/" rel="nofollow">free credit report</a></p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Brian Hanley</title>
		<link>http://www.virology.ws/2009/02/26/dreaming-inactivated-poliovirus-vaccine/comment-page-1/#comment-17133</link>
		<dc:creator>Brian Hanley</dc:creator>
		<pubDate>Sat, 22 Aug 2009 00:16:13 +0000</pubDate>
		<guid isPermaLink="false">http://www.virology.ws/?p=736#comment-17133</guid>
		<description>Thanks. Sent an email off to a guy who trained me a few years ago.  Maybe something will come of it.</description>
		<content:encoded><![CDATA[<p>Thanks. Sent an email off to a guy who trained me a few years ago.  Maybe something will come of it.</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: profvrr</title>
		<link>http://www.virology.ws/2009/02/26/dreaming-inactivated-poliovirus-vaccine/comment-page-1/#comment-17132</link>
		<dc:creator>profvrr</dc:creator>
		<pubDate>Fri, 21 Aug 2009 23:46:33 +0000</pubDate>
		<guid isPermaLink="false">http://www.virology.ws/?p=736#comment-17132</guid>
		<description>The Polio Research Committee of the Global Polio Eradication&lt;br&gt;Initiative is funding work to produce a poliovirus VLP-like vaccine. I&lt;br&gt;say VLP like because some viral RNA will be present, but it will lack&lt;br&gt;sequences encoding the capsid region. The capsid proteins will be&lt;br&gt;provided by a packaging cell line. See&lt;br&gt;&lt;a href=&quot;http://www.polioeradication.org/content/poliopipeline/PolioPipeline_04.pdf&quot; rel=&quot;nofollow&quot;&gt;http://www.polioeradication.org/content/poliopi...&lt;/a&gt;.&lt;br&gt;I&#039;m not sure this is the best way to go but at least it&#039;s a start.&lt;br&gt;Anyone interested in developing alternative polio vaccines can apply&lt;br&gt;for a research grant. Presumably the best leads will be pushed further&lt;br&gt;by the Initiative.</description>
		<content:encoded><![CDATA[<p>The Polio Research Committee of the Global Polio Eradication<br />Initiative is funding work to produce a poliovirus VLP-like vaccine. I<br />say VLP like because some viral RNA will be present, but it will lack<br />sequences encoding the capsid region. The capsid proteins will be<br />provided by a packaging cell line. See<br /><a href="http://www.polioeradication.org/content/poliopipeline/PolioPipeline_04.pdf" rel="nofollow">http://www.polioeradication.org/content/poliopi&#8230;</a>.<br />I&#39;m not sure this is the best way to go but at least it&#39;s a start.<br />Anyone interested in developing alternative polio vaccines can apply<br />for a research grant. Presumably the best leads will be pushed further<br />by the Initiative.</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Brian Hanley</title>
		<link>http://www.virology.ws/2009/02/26/dreaming-inactivated-poliovirus-vaccine/comment-page-1/#comment-17130</link>
		<dc:creator>Brian Hanley</dc:creator>
		<pubDate>Fri, 21 Aug 2009 23:30:22 +0000</pubDate>
		<guid isPermaLink="false">http://www.virology.ws/?p=736#comment-17130</guid>
		<description>Yes, too much so. But it isn&#039;t necessary for such a vaccine to be commercialized to use it in the end stages of eradication in Africa. WHO could fund it, and handle the vaccine distribution. After all, people like Yilma act as the practical repository for the rinderpest vaccine that is used in Africa in animals. So could the Gates foundation fund it. &lt;br&gt;&lt;br&gt;Such a vaccine could be developed in an academic lab and proved through to Rhesus studies in 3-4 years for less than $1MM. A crash program could do it in 1 year.   The reason to bring in commercial outfits is when you need huge volumes and to make use of their distribution channels. That wouldn&#039;t be necessary or useful in this case.  Considering the importance, and the amount of money spent on other things, it should be done.</description>
		<content:encoded><![CDATA[<p>Yes, too much so. But it isn&#39;t necessary for such a vaccine to be commercialized to use it in the end stages of eradication in Africa. WHO could fund it, and handle the vaccine distribution. After all, people like Yilma act as the practical repository for the rinderpest vaccine that is used in Africa in animals. So could the Gates foundation fund it. </p>
<p>Such a vaccine could be developed in an academic lab and proved through to Rhesus studies in 3-4 years for less than $1MM. A crash program could do it in 1 year.   The reason to bring in commercial outfits is when you need huge volumes and to make use of their distribution channels. That wouldn&#39;t be necessary or useful in this case.  Considering the importance, and the amount of money spent on other things, it should be done.</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: profvrr</title>
		<link>http://www.virology.ws/2009/02/26/dreaming-inactivated-poliovirus-vaccine/comment-page-1/#comment-17129</link>
		<dc:creator>profvrr</dc:creator>
		<pubDate>Fri, 21 Aug 2009 23:01:32 +0000</pubDate>
		<guid isPermaLink="false">http://www.virology.ws/?p=736#comment-17129</guid>
		<description>All your points are correct. Your idea for a novel vaccine would avoid&lt;br&gt;the problems of reversion. Unfortunately few companies are willing to&lt;br&gt;invest in developing a new polio vaccine with the disease nearly&lt;br&gt;eradicated. It&#039;s a sad fact that economics drives vaccine development.</description>
		<content:encoded><![CDATA[<p>All your points are correct. Your idea for a novel vaccine would avoid<br />the problems of reversion. Unfortunately few companies are willing to<br />invest in developing a new polio vaccine with the disease nearly<br />eradicated. It&#39;s a sad fact that economics drives vaccine development.</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Brian Hanley</title>
		<link>http://www.virology.ws/2009/02/26/dreaming-inactivated-poliovirus-vaccine/comment-page-1/#comment-17103</link>
		<dc:creator>Brian Hanley</dc:creator>
		<pubDate>Thu, 20 Aug 2009 16:13:40 +0000</pubDate>
		<guid isPermaLink="false">http://www.virology.ws/?p=736#comment-17103</guid>
		<description>Well, that didn&#039;t work. Formatting was lost. Trying again.&lt;br&gt;(This is from my own unpublished metanalysis of measles vaccine coverage.) &lt;br&gt;Cite _Location Efficacy __Coverage _Efficacy __Coverage _Net _____Net coverage&lt;br&gt;____________1 dose % _1 dose % __2 dose % __2 dose % _coverage _deficit/overage&lt;br&gt;&lt;br&gt;1 _Romania ___89.0%___52.0%____96.0%____6.0%____52.0%____-38.0%&lt;br&gt;2 _Masivingo__73.0%___75.0%_____________________54.8%____-35.3%&lt;br&gt;___ Zimbabwe&lt;br&gt;3 _Mashonaland 84.9%___67.6%_____________________57.4%____-32.6%&lt;br&gt;__Zimbabwe	&lt;br&gt;4 _Harare _____68.0%___85.0%_____________________57.8%____-32.2%&lt;br&gt;__Zimbabwe	&lt;br&gt;5 _Singapore ___97.8%___93.0%_____________________91.0%______1.0%&lt;br&gt;6 _Duisburg ____98.1% ___25.0%___99.4%___70.4%_____94.5%______4.5%&lt;br&gt; __Germany	&lt;br&gt;7 _Incheon_____88.8%____7.0%___98.0%___90.8%_____95.2%______5.2%&lt;br&gt; __Korea	&lt;br&gt;8 _Pennsylvania_98.0%____3.9%___98.6%___94.9%_____97.4%_______7.4%&lt;br&gt;__USA	&lt;br&gt;        Table 1 – Survey of vaccine efficacy and net vaccine coverage with eradication deficit. &lt;br&gt;&lt;br&gt;References&lt;br&gt;1.	Hennessey, Karen A. et al. Measles epidemic in Romania, 1996-1998: assessment of vaccine effectiveness by case-control and cohort studies. American Journal of Epidemiology 150, 1250-1257 December 1 (1999). &lt;br&gt;2.	Mudzamiri, W S, Peterson, D E, Marufu, T, Biellik, R J &amp; L&#039;Herminez, M. Measles vaccine efficacy in Masvingo district, Zimbabwe. Central African Journal of Medicine 42, 195-197 July (1996). &lt;br&gt;3.	Uyirwoth, G P. Measles in Mashonaland Central Province: Zimbabwe. East Africa Medical Journal 70, 455-459 July (1993). &lt;br&gt;4.	Mahomva, A I, Moyo, I M &amp; Mbengeranwa, I O. Evaluation of a measles vaccine efficacy during a measles outbreak in Mbare, City of Harare Zimbabwe. Central African Journal of Medicine 43, 254-256 September (1997). &lt;br&gt;5.	Ong, G, Rasidah, N, Wan, S &amp; Cutter, J. Outbreak of measles in primary school students with high first dose MMR vaccination coverage. Singapore Medical Journal 48, 656 661 (2007). &lt;br&gt;6.	Wichmann, O et al. Large measles outbreak at a German public school, 2006. Pediatric Infectious Disease Journal 26, 782-786 September (2007). &lt;br&gt;7.	So, Jae Sung, Go, Un Yeong, Lee, Dong Han, Park, Koang Suk &amp; Lee2, Jong Koo. Epidemiological investigation of a measles outbreak in a preschool in incheon, Korea, 2006. J Prev Med Pub Health 41, 153-158 May (2008). &lt;br&gt;8.	Yeung, Lorraine F. et al. A limited measles outbreak in a highly vaccinated US boarding school. Pediatrics 116, 1287-1291 December (2005).</description>
		<content:encoded><![CDATA[<p>Well, that didn&#39;t work. Formatting was lost. Trying again.<br />(This is from my own unpublished metanalysis of measles vaccine coverage.) <br />Cite _Location Efficacy __Coverage _Efficacy __Coverage _Net _____Net coverage<br />____________1 dose % _1 dose % __2 dose % __2 dose % _coverage _deficit/overage</p>
<p>1 _Romania ___89.0%___52.0%____96.0%____6.0%____52.0%____-38.0%<br />2 _Masivingo__73.0%___75.0%_____________________54.8%____-35.3%<br />___ Zimbabwe<br />3 _Mashonaland 84.9%___67.6%_____________________57.4%____-32.6%<br />__Zimbabwe	<br />4 _Harare _____68.0%___85.0%_____________________57.8%____-32.2%<br />__Zimbabwe	<br />5 _Singapore ___97.8%___93.0%_____________________91.0%______1.0%<br />6 _Duisburg ____98.1% ___25.0%___99.4%___70.4%_____94.5%______4.5%<br /> __Germany	<br />7 _Incheon_____88.8%____7.0%___98.0%___90.8%_____95.2%______5.2%<br /> __Korea	<br />8 _Pennsylvania_98.0%____3.9%___98.6%___94.9%_____97.4%_______7.4%<br />__USA	<br />        Table 1 – Survey of vaccine efficacy and net vaccine coverage with eradication deficit. </p>
<p>References<br />1.	Hennessey, Karen A. et al. Measles epidemic in Romania, 1996-1998: assessment of vaccine effectiveness by case-control and cohort studies. American Journal of Epidemiology 150, 1250-1257 December 1 (1999). <br />2.	Mudzamiri, W S, Peterson, D E, Marufu, T, Biellik, R J &#038; L&#39;Herminez, M. Measles vaccine efficacy in Masvingo district, Zimbabwe. Central African Journal of Medicine 42, 195-197 July (1996). <br />3.	Uyirwoth, G P. Measles in Mashonaland Central Province: Zimbabwe. East Africa Medical Journal 70, 455-459 July (1993). <br />4.	Mahomva, A I, Moyo, I M &#038; Mbengeranwa, I O. Evaluation of a measles vaccine efficacy during a measles outbreak in Mbare, City of Harare Zimbabwe. Central African Journal of Medicine 43, 254-256 September (1997). <br />5.	Ong, G, Rasidah, N, Wan, S &#038; Cutter, J. Outbreak of measles in primary school students with high first dose MMR vaccination coverage. Singapore Medical Journal 48, 656 661 (2007). <br />6.	Wichmann, O et al. Large measles outbreak at a German public school, 2006. Pediatric Infectious Disease Journal 26, 782-786 September (2007). <br />7.	So, Jae Sung, Go, Un Yeong, Lee, Dong Han, Park, Koang Suk &#038; Lee2, Jong Koo. Epidemiological investigation of a measles outbreak in a preschool in incheon, Korea, 2006. J Prev Med Pub Health 41, 153-158 May (2008). <br />8.	Yeung, Lorraine F. et al. A limited measles outbreak in a highly vaccinated US boarding school. Pediatrics 116, 1287-1291 December (2005).</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Brian Hanley</title>
		<link>http://www.virology.ws/2009/02/26/dreaming-inactivated-poliovirus-vaccine/comment-page-1/#comment-17102</link>
		<dc:creator>Brian Hanley</dc:creator>
		<pubDate>Thu, 20 Aug 2009 16:00:53 +0000</pubDate>
		<guid isPermaLink="false">http://www.virology.ws/?p=736#comment-17102</guid>
		<description>(This is from my own unpublished metanalysis of measles vaccine coverage.) &lt;br&gt;Cite  Location  Efficacy    Coverage 	  Efficacy 	 Coverage 	 Net               Net coverage&lt;br&gt;                              1 dose %   1 dose %       2 dose %     2 dose %      coverage   deficit/overage&lt;br&gt; &lt;br&gt;1    Romania	89.0%	   52.0%           96.0%           6.0%            52.0%         -38.0%&lt;br&gt;2    Masivingo	73.0%	   75.0%                                                         54.8%	       -35.3%&lt;br&gt;      Zimbabwe&lt;br&gt;3    Mashonaland  84.9%  67.6%	                                        	  57.4%	       -32.6%&lt;br&gt;      Zimbabwe	&lt;br&gt;4    Harare               68.0%   85.0%                                     			  57.8%	       -32.2%&lt;br&gt;       Zimbabwe	&lt;br&gt;5    Singapore	    97.8%   93.0%			                                  91.0%	            1.0%&lt;br&gt;6    Duisburg           98.1%   25.0%	   99.4%	    70.4%	          94.5%     	    4.5%&lt;br&gt;       Germany	&lt;br&gt;7    Incheon            88.8%     7.0%	   98.0%     90.8%	           95.2%	            5.2%&lt;br&gt;       Korea	&lt;br&gt;8    Pennsylvania  98.0%	3.9%	   98.6%	     94.9%	           97.4%	     7.4%&lt;br&gt;       USA	&lt;br&gt;        Table 1 – Survey of vaccine efficacy and net vaccine coverage with eradication deficit. &lt;br&gt;&lt;br&gt;References&lt;br&gt;1.	Hennessey, Karen A. et al. Measles epidemic in Romania, 1996-1998: assessment of vaccine effectiveness by case-control and cohort studies. American Journal of Epidemiology 150, 1250-1257 December 1 (1999). &lt;br&gt;2.	Mudzamiri, W S, Peterson, D E, Marufu, T, Biellik, R J &amp; L&#039;Herminez, M. Measles vaccine efficacy in Masvingo district, Zimbabwe. Central African Journal of Medicine 42, 195-197 July (1996). &lt;br&gt;3.	Uyirwoth, G P. Measles in Mashonaland Central Province: Zimbabwe. East Africa Medical Journal 70, 455-459 July (1993). &lt;br&gt;4.	Mahomva, A I, Moyo, I M &amp; Mbengeranwa, I O. Evaluation of a measles vaccine efficacy during a measles outbreak in Mbare, City of Harare Zimbabwe. Central African Journal of Medicine 43, 254-256 September (1997). &lt;br&gt;5.	Ong, G, Rasidah, N, Wan, S &amp; Cutter, J. Outbreak of measles in primary school students with high first dose MMR vaccination coverage. Singapore Medical Journal 48, 656 661 (2007). &lt;br&gt;6.	Wichmann, O et al. Large measles outbreak at a German public school, 2006. Pediatric Infectious Disease Journal 26, 782-786 September (2007). &lt;br&gt;7.	So, Jae Sung, Go, Un Yeong, Lee, Dong Han, Park, Koang Suk &amp; Lee2, Jong Koo. Epidemiological investigation of a measles outbreak in a preschool in incheon, Korea, 2006. J Prev Med Pub Health 41, 153-158 May (2008). &lt;br&gt;8.	Yeung, Lorraine F. et al. A limited measles outbreak in a highly vaccinated US boarding school. Pediatrics 116, 1287-1291 December (2005).</description>
		<content:encoded><![CDATA[<p>(This is from my own unpublished metanalysis of measles vaccine coverage.) <br />Cite  Location  Efficacy    Coverage 	  Efficacy 	 Coverage 	 Net               Net coverage<br />                              1 dose %   1 dose %       2 dose %     2 dose %      coverage   deficit/overage</p>
<p>1    Romania	89.0%	   52.0%           96.0%           6.0%            52.0%         -38.0%<br />2    Masivingo	73.0%	   75.0%                                                         54.8%	       -35.3%<br />      Zimbabwe<br />3    Mashonaland  84.9%  67.6%	                                        	  57.4%	       -32.6%<br />      Zimbabwe	<br />4    Harare               68.0%   85.0%                                     			  57.8%	       -32.2%<br />       Zimbabwe	<br />5    Singapore	    97.8%   93.0%			                                  91.0%	            1.0%<br />6    Duisburg           98.1%   25.0%	   99.4%	    70.4%	          94.5%     	    4.5%<br />       Germany	<br />7    Incheon            88.8%     7.0%	   98.0%     90.8%	           95.2%	            5.2%<br />       Korea	<br />8    Pennsylvania  98.0%	3.9%	   98.6%	     94.9%	           97.4%	     7.4%<br />       USA	<br />        Table 1 – Survey of vaccine efficacy and net vaccine coverage with eradication deficit. </p>
<p>References<br />1.	Hennessey, Karen A. et al. Measles epidemic in Romania, 1996-1998: assessment of vaccine effectiveness by case-control and cohort studies. American Journal of Epidemiology 150, 1250-1257 December 1 (1999). <br />2.	Mudzamiri, W S, Peterson, D E, Marufu, T, Biellik, R J &#038; L&#39;Herminez, M. Measles vaccine efficacy in Masvingo district, Zimbabwe. Central African Journal of Medicine 42, 195-197 July (1996). <br />3.	Uyirwoth, G P. Measles in Mashonaland Central Province: Zimbabwe. East Africa Medical Journal 70, 455-459 July (1993). <br />4.	Mahomva, A I, Moyo, I M &#038; Mbengeranwa, I O. Evaluation of a measles vaccine efficacy during a measles outbreak in Mbare, City of Harare Zimbabwe. Central African Journal of Medicine 43, 254-256 September (1997). <br />5.	Ong, G, Rasidah, N, Wan, S &#038; Cutter, J. Outbreak of measles in primary school students with high first dose MMR vaccination coverage. Singapore Medical Journal 48, 656 661 (2007). <br />6.	Wichmann, O et al. Large measles outbreak at a German public school, 2006. Pediatric Infectious Disease Journal 26, 782-786 September (2007). <br />7.	So, Jae Sung, Go, Un Yeong, Lee, Dong Han, Park, Koang Suk &#038; Lee2, Jong Koo. Epidemiological investigation of a measles outbreak in a preschool in incheon, Korea, 2006. J Prev Med Pub Health 41, 153-158 May (2008). <br />8.	Yeung, Lorraine F. et al. A limited measles outbreak in a highly vaccinated US boarding school. Pediatrics 116, 1287-1291 December (2005).</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Brian Hanley</title>
		<link>http://www.virology.ws/2009/02/26/dreaming-inactivated-poliovirus-vaccine/comment-page-1/#comment-17101</link>
		<dc:creator>Brian Hanley</dc:creator>
		<pubDate>Thu, 20 Aug 2009 15:41:59 +0000</pubDate>
		<guid isPermaLink="false">http://www.virology.ws/?p=736#comment-17101</guid>
		<description>We do have experience with other such vaccines, for instance, measles in those regions. Net vaccination rate (efficacy fraction x fraction vaccinated) is around 50%. &lt;br&gt;&lt;br&gt;Regarding revertants, ok, however, I think the argument stands that an old revertant strain could circulate in the population after elimination of live vaccine. There is also another method of working on revertants, and that is to change the attenuated strain to have more critical mutations. &lt;br&gt;&lt;br&gt;There is yet another strategy, and that is to make a live recombinant vaccine with a different virus expressing the important proteins of polio. This method would be the safest and most effective.</description>
		<content:encoded><![CDATA[<p>We do have experience with other such vaccines, for instance, measles in those regions. Net vaccination rate (efficacy fraction x fraction vaccinated) is around 50%. </p>
<p>Regarding revertants, ok, however, I think the argument stands that an old revertant strain could circulate in the population after elimination of live vaccine. There is also another method of working on revertants, and that is to change the attenuated strain to have more critical mutations. </p>
<p>There is yet another strategy, and that is to make a live recombinant vaccine with a different virus expressing the important proteins of polio. This method would be the safest and most effective.</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: profvrr</title>
		<link>http://www.virology.ws/2009/02/26/dreaming-inactivated-poliovirus-vaccine/comment-page-1/#comment-17098</link>
		<dc:creator>profvrr</dc:creator>
		<pubDate>Thu, 20 Aug 2009 07:10:01 +0000</pubDate>
		<guid isPermaLink="false">http://www.virology.ws/?p=736#comment-17098</guid>
		<description>Henderson&#039;s view was based on several factors, including the high cost&lt;br&gt;of IPV and the lack of experience with this vaccine in developing&lt;br&gt;countries. With respect to vaccine revertants, they have been shown to&lt;br&gt;circulate even in countries with excellent sanitation (USA). The type&lt;br&gt;2 polio in Nigeria is clearly vaccine derived - a fact that can be&lt;br&gt;deduced by sequence analysis of viral isolates. This information shows&lt;br&gt;that the type 2 virus is not wild virus.</description>
		<content:encoded><![CDATA[<p>Henderson&#39;s view was based on several factors, including the high cost<br />of IPV and the lack of experience with this vaccine in developing<br />countries. With respect to vaccine revertants, they have been shown to<br />circulate even in countries with excellent sanitation (USA). The type<br />2 polio in Nigeria is clearly vaccine derived &#8211; a fact that can be<br />deduced by sequence analysis of viral isolates. This information shows<br />that the type 2 virus is not wild virus.</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Brian Hanley</title>
		<link>http://www.virology.ws/2009/02/26/dreaming-inactivated-poliovirus-vaccine/comment-page-1/#comment-17016</link>
		<dc:creator>Brian Hanley</dc:creator>
		<pubDate>Tue, 18 Aug 2009 11:36:32 +0000</pubDate>
		<guid isPermaLink="false">http://www.virology.ws/?p=736#comment-17016</guid>
		<description>I am pretty familiar with the smallpox eradication effort, and I completely understand why Henderson said what he did. Smallpox was almost not eradicated, but there were many factors that helped this to happen, foremost among them that smallpox has no known subclinical manifestations that do not cause disfigurement. Polio, under normal circumstances with no vaccine is approximately 95% subclinical manifestation with little apparent disease. That means that people can be infected with, and shed the virus with no clinical indications that they are doing so. &lt;br&gt;&lt;br&gt;Smallpox is different than most viral diseases in that immunity to the vaccine provides 100% sterilizing immunity to the virus, and there is no disease transmission. Most vaccines result in a bell curve of titers and some level of circulation of the disease in subclinical form. I do not have a curve of the subclinical manifestation of polio after trivalent vaccine inoculation, but clearly, it is happening. Subclinical illness potential is 100% in populations vaccinated using killed virus vaccines like IPV.  Since IGA is what combats polio in the gut, and IPV is a injected, it will produce primary titers of IgG, and those titers will be lower than after infection with polio, which will guarantee that to achieve more complete immunity to the disease will require subclinical infection with the virus. That means  that subclinical polio will continue to circulate even after IPV is used. It will circulate at higher levels because killed vaccine produces lower titers.&lt;br&gt;&lt;br&gt;The problem with polio in Africa is twofold. First, it is possibly reverting, although it is very doubtful that it reverts in every case of live vaccine. That brings us to the second problem, which is sanitation. That part of the world has terrible sanitation, and that is how revertants (if they are revertants at all, and not original virus strains that continued to circulate) are spread. &lt;br&gt;&lt;br&gt;But that brings us to the third problem, which is the question of where the polio came from. There is an assumption that it had to come from the trivalent vaccine because it is presumed that after administration of the vaccine subclinical illness cannot occur in humans and the virus cannot reproduce and spread. But I am certain that this fundamental assumption is not correct. And in an environment in which fecal oral transmission is a norm, the virus can stay alive for generations without being noticed.</description>
		<content:encoded><![CDATA[<p>I am pretty familiar with the smallpox eradication effort, and I completely understand why Henderson said what he did. Smallpox was almost not eradicated, but there were many factors that helped this to happen, foremost among them that smallpox has no known subclinical manifestations that do not cause disfigurement. Polio, under normal circumstances with no vaccine is approximately 95% subclinical manifestation with little apparent disease. That means that people can be infected with, and shed the virus with no clinical indications that they are doing so. </p>
<p>Smallpox is different than most viral diseases in that immunity to the vaccine provides 100% sterilizing immunity to the virus, and there is no disease transmission. Most vaccines result in a bell curve of titers and some level of circulation of the disease in subclinical form. I do not have a curve of the subclinical manifestation of polio after trivalent vaccine inoculation, but clearly, it is happening. Subclinical illness potential is 100% in populations vaccinated using killed virus vaccines like IPV.  Since IGA is what combats polio in the gut, and IPV is a injected, it will produce primary titers of IgG, and those titers will be lower than after infection with polio, which will guarantee that to achieve more complete immunity to the disease will require subclinical infection with the virus. That means  that subclinical polio will continue to circulate even after IPV is used. It will circulate at higher levels because killed vaccine produces lower titers.</p>
<p>The problem with polio in Africa is twofold. First, it is possibly reverting, although it is very doubtful that it reverts in every case of live vaccine. That brings us to the second problem, which is sanitation. That part of the world has terrible sanitation, and that is how revertants (if they are revertants at all, and not original virus strains that continued to circulate) are spread. </p>
<p>But that brings us to the third problem, which is the question of where the polio came from. There is an assumption that it had to come from the trivalent vaccine because it is presumed that after administration of the vaccine subclinical illness cannot occur in humans and the virus cannot reproduce and spread. But I am certain that this fundamental assumption is not correct. And in an environment in which fecal oral transmission is a norm, the virus can stay alive for generations without being noticed.</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: jatupon</title>
		<link>http://www.virology.ws/2009/02/26/dreaming-inactivated-poliovirus-vaccine/comment-page-1/#comment-23415</link>
		<dc:creator>jatupon</dc:creator>
		<pubDate>Fri, 29 May 2009 18:18:00 +0000</pubDate>
		<guid isPermaLink="false">http://www.virology.ws/?p=736#comment-23415</guid>
		<description>Hi... that was great stuff.. I really like reading on this subject  Could you tell me more on that... I love to explore
Great post, really help me alot. Thanks.
visit my site &lt;a href=&quot;http://www.orchardbankservices.com&quot; rel=&quot;nofollow&quot;&gt;www.orchardbank.com&lt;/a&gt;.</description>
		<content:encoded><![CDATA[<p>Hi&#8230; that was great stuff.. I really like reading on this subject  Could you tell me more on that&#8230; I love to explore<br />
Great post, really help me alot. Thanks.<br />
visit my site <a href="http://www.orchardbankservices.com" rel="nofollow">http://www.orchardbank.com</a>.</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Bruce</title>
		<link>http://www.virology.ws/2009/02/26/dreaming-inactivated-poliovirus-vaccine/comment-page-1/#comment-23407</link>
		<dc:creator>Bruce</dc:creator>
		<pubDate>Tue, 12 May 2009 15:32:00 +0000</pubDate>
		<guid isPermaLink="false">http://www.virology.ws/?p=736#comment-23407</guid>
		<description>I just want to know that anyone accepts ur logic and anyone praised you for this..Because still i have doubt in this..
&lt;a href=&quot;http://www.on-freeannualcreditreport.com/annualcreditreport/what-is-a-good-credit-score.html&quot; rel=&quot;nofollow&quot;&gt;good credit score&lt;/a&gt;</description>
		<content:encoded><![CDATA[<p>I just want to know that anyone accepts ur logic and anyone praised you for this..Because still i have doubt in this..<br />
<a href="http://www.on-freeannualcreditreport.com/annualcreditreport/what-is-a-good-credit-score.html" rel="nofollow">good credit score</a></p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Mambo</title>
		<link>http://www.virology.ws/2009/02/26/dreaming-inactivated-poliovirus-vaccine/comment-page-1/#comment-580</link>
		<dc:creator>Mambo</dc:creator>
		<pubDate>Wed, 22 Apr 2009 16:26:15 +0000</pubDate>
		<guid isPermaLink="false">http://www.virology.ws/?p=736#comment-580</guid>
		<description>Yeah i read about this already..Seems to be a major prob..Let us see how it gets solved..&lt;br&gt;&lt;a href=&quot;http://us-creditcards.com&quot; rel=&quot;follow&quot; rel=&quot;nofollow&quot;&gt;credit card reviews&lt;/a&gt;</description>
		<content:encoded><![CDATA[<p>Yeah i read about this already..Seems to be a major prob..Let us see how it gets solved..<br /><a href="http://us-creditcards.com" rel="follow" rel="nofollow">credit card reviews</a></p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Polio among the Amish</title>
		<link>http://www.virology.ws/2009/02/26/dreaming-inactivated-poliovirus-vaccine/comment-page-1/#comment-298</link>
		<dc:creator>Polio among the Amish</dc:creator>
		<pubDate>Mon, 09 Mar 2009 14:02:57 +0000</pubDate>
		<guid isPermaLink="false">http://www.virology.ws/?p=736#comment-298</guid>
		<description>[...] VDVPs could spark an outbreak of poliomyelitis.  Another reason for switching to IPV rather than stopping immunization [...]</description>
		<content:encoded><![CDATA[<p>[...] VDVPs could spark an outbreak of poliomyelitis.  Another reason for switching to IPV rather than stopping immunization [...]</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: latino</title>
		<link>http://www.virology.ws/2009/02/26/dreaming-inactivated-poliovirus-vaccine/comment-page-1/#comment-454</link>
		<dc:creator>latino</dc:creator>
		<pubDate>Mon, 02 Mar 2009 22:13:48 +0000</pubDate>
		<guid isPermaLink="false">http://www.virology.ws/?p=736#comment-454</guid>
		<description>Raivo Pommer&lt;br&gt;Spanische Banken&lt;br&gt;&lt;a href=&quot;mailto:-raimo1@hot.ee&quot; rel=&quot;nofollow&quot;&gt;-raimo1@hot.ee&lt;/a&gt;&lt;br&gt;&lt;br&gt;Die Erste Bank hat überraschend einen neuen Großaktionär aus Spanien bekommen. Die größte spanische Sparkasse, Criteria CaixaCorp, teilte am Montag bei einer Pressekonferenz in Barcelona mit, dass sie über die Börse 4,9 Prozent der Erste-Aktien erworben hat. Die Zukäufe seien schon im Vorjahr erfolgt, sagte Criteria-Chef Ricardo Forensa. Den Kaufpreis bezifferte der Banker mit 628 Mio. Euro.&lt;br&gt;&lt;br&gt;Die Spanier dürften damit durchschnittlich zwischen 35 und 40 Euro pro Aktie hingelegt haben. Inzwischen ist der Kurs der Erste Bank an der Börse eingebrochen. Am Montagnachmittag kostete das Papier 7,46 Euro</description>
		<content:encoded><![CDATA[<p>Raivo Pommer<br />Spanische Banken<br /><a href="mailto:-raimo1@hot.ee" rel="nofollow">-raimo1@hot.ee</a></p>
<p>Die Erste Bank hat überraschend einen neuen Großaktionär aus Spanien bekommen. Die größte spanische Sparkasse, Criteria CaixaCorp, teilte am Montag bei einer Pressekonferenz in Barcelona mit, dass sie über die Börse 4,9 Prozent der Erste-Aktien erworben hat. Die Zukäufe seien schon im Vorjahr erfolgt, sagte Criteria-Chef Ricardo Forensa. Den Kaufpreis bezifferte der Banker mit 628 Mio. Euro.</p>
<p>Die Spanier dürften damit durchschnittlich zwischen 35 und 40 Euro pro Aktie hingelegt haben. Inzwischen ist der Kurs der Erste Bank an der Börse eingebrochen. Am Montagnachmittag kostete das Papier 7,46 Euro</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: franck mon</title>
		<link>http://www.virology.ws/2009/02/26/dreaming-inactivated-poliovirus-vaccine/comment-page-1/#comment-453</link>
		<dc:creator>franck mon</dc:creator>
		<pubDate>Fri, 27 Feb 2009 11:41:30 +0000</pubDate>
		<guid isPermaLink="false">http://www.virology.ws/?p=736#comment-453</guid>
		<description>Paribas grosbank BNP in Paris krisis&lt;br&gt;&lt;br&gt;von Raivo &lt;a href=&quot;mailto:Pommer-Eesti-raimo1@hot.ee&quot; rel=&quot;nofollow&quot;&gt;Pommer-Eesti-raimo1@hot.ee&lt;/a&gt;&lt;br&gt;&lt;br&gt;Peinlicher Computerfehler bei der französischen Großbank BNP Paribas: Das Finanzinstitut hat von zahlreichen Kundenkonten aus Versehen zu viel Geld abgebucht.&lt;br&gt;&lt;br&gt;Fast 600 000 Transaktionen wie Überweisungen wurden wegen eines Softwarefehlers irrtümlich zweimal oder sogar dreimal ausgeführt. Betroffen seien einige zehntausend Konten, bestätigte ein Sprecher der Bank am Freitag.&lt;br&gt;&lt;br&gt;Das Institut kündigte an, die Fehlbuchungen innerhalb von 48 Stunden wieder rückgängig zu machen. &quot;Die Kunden werden natürlich nicht die Konsequenzen dieses Vorfalls tragen&quot;, hieß es bei BNP Paribas. Auch wer durch die Abbuchungen in die roten Zahlen gerutscht sei, müsse keine Zusatzkosten durch Zinsen befürchten. Wie viel Geld fälschlicherweise den Besitzer wechselte, wollte die Bank zunächst nicht sagen. Auch zur Ursache des Computerfehlers gab es keine Angaben.</description>
		<content:encoded><![CDATA[<p>Paribas grosbank BNP in Paris krisis</p>
<p>von Raivo <a href="mailto:Pommer-Eesti-raimo1@hot.ee" rel="nofollow">Pommer-Eesti-raimo1@hot.ee</a></p>
<p>Peinlicher Computerfehler bei der französischen Großbank BNP Paribas: Das Finanzinstitut hat von zahlreichen Kundenkonten aus Versehen zu viel Geld abgebucht.</p>
<p>Fast 600 000 Transaktionen wie Überweisungen wurden wegen eines Softwarefehlers irrtümlich zweimal oder sogar dreimal ausgeführt. Betroffen seien einige zehntausend Konten, bestätigte ein Sprecher der Bank am Freitag.</p>
<p>Das Institut kündigte an, die Fehlbuchungen innerhalb von 48 Stunden wieder rückgängig zu machen. &#8220;Die Kunden werden natürlich nicht die Konsequenzen dieses Vorfalls tragen&#8221;, hieß es bei BNP Paribas. Auch wer durch die Abbuchungen in die roten Zahlen gerutscht sei, müsse keine Zusatzkosten durch Zinsen befürchten. Wie viel Geld fälschlicherweise den Besitzer wechselte, wollte die Bank zunächst nicht sagen. Auch zur Ursache des Computerfehlers gab es keine Angaben.</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: profvrr</title>
		<link>http://www.virology.ws/2009/02/26/dreaming-inactivated-poliovirus-vaccine/comment-page-1/#comment-183</link>
		<dc:creator>profvrr</dc:creator>
		<pubDate>Thu, 26 Feb 2009 19:40:17 +0000</pubDate>
		<guid isPermaLink="false">http://www.virology.ws/?p=736#comment-183</guid>
		<description>Standard protocol, unfortunately, is to ignore previous errors. I&lt;br&gt;would not expect that he would remember who I am, nor what I said at&lt;br&gt;the meeting. And I certainly did not expect an email. But see&lt;br&gt;&lt;a href=&quot;http://www.dovdox.com&quot; rel=&quot;nofollow&quot;&gt;www.dovdox.com&lt;/a&gt; for further elaboration of the situation.</description>
		<content:encoded><![CDATA[<p>Standard protocol, unfortunately, is to ignore previous errors. I<br />would not expect that he would remember who I am, nor what I said at<br />the meeting. And I certainly did not expect an email. But see<br /><a href="http://www.dovdox.com" rel="nofollow">http://www.dovdox.com</a> for further elaboration of the situation.</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: ET</title>
		<link>http://www.virology.ws/2009/02/26/dreaming-inactivated-poliovirus-vaccine/comment-page-1/#comment-182</link>
		<dc:creator>ET</dc:creator>
		<pubDate>Thu, 26 Feb 2009 19:16:24 +0000</pubDate>
		<guid isPermaLink="false">http://www.virology.ws/?p=736#comment-182</guid>
		<description>So, does he acknowledge that your logic was valid and idea sound in an email? Or when someones hubris is exposed, do they just try to forget that it ever happened at all?</description>
		<content:encoded><![CDATA[<p>So, does he acknowledge that your logic was valid and idea sound in an email? Or when someones hubris is exposed, do they just try to forget that it ever happened at all?</p>
]]></content:encoded>
	</item>
</channel>
</rss>

